Efficacy of ambrisentan in the treatment of digital ulcers in patients with systemic sclerosis: A preliminary study

Rheumatology (United Kingdom)

Volumn 52, Issue 6, 2013, Pages 1142-1144

  Parisi, Simone ^a   Peroni, Clara L ^a   Laganà, Angela ^a   Scarati, Marco ^a   Ambrogio, Federico ^a   Bruzzone, Maria ^a   Fusaro, Enrico ^a  

^a CITTÀ DELLA SALUTE E DELLA SCIENZA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMBRISENTAN; BOSENTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN; PROSTANOID;

DISEASE DURATION; DRUG EFFICACY; DRUG TOLERABILITY; FINGER ULCER; INCIDENCE; LETTER; OFF LABEL DRUG USE; PRIORITY JOURNAL; SYSTEMIC SCLEROSIS; TREATMENT DURATION; VISUAL ANALOG SCALE;

ADULT; AGED; HUMANS; MIDDLE AGED; OFF-LABEL USE; PHENYLPROPIONATES; PILOT PROJECTS; PYRIDAZINES; SCLERODERMA, SYSTEMIC; SKIN ULCER; TREATMENT OUTCOME;

EID: 84878150325     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ket019     Document Type: Letter

References (10)

1. Steen VD, Medsger TA. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000;43:2437-44.
2. Kahaleh MB. Raynaud phenomenon and the vascular disease in scleroderma. Curr Opin Rheumatol 2004;16:718-22.
3. Mayes MD. Endothelin and endothelin receptor antagonists in systemic rheumatic disease. Arthritis Rheum 2003; 48:1190-9.
4. Korn JH, Mayes M, Matucci Cerinic M et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 2004;50:3985-93.
5. Matucci-Cerinic M, Denton CP, Furst DE et al. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 2011;70:32-8.
6. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
7. Garci{dotless}́a de la Pen{ogonek} a-Lefebvre P, Rodri{dotless}́guez Rubio S, Valero Exposito M et al. Long-term experience of bosentan for treating ulcers and healed ulcers in systemic sclerosis patients. Rheumatology 2008;47:464-6.
8. Arefiev K, Fiorentino DF, Chung L. Endothelin receptor antagonists for the treatment of Raynaud's phenomenon and digital ulcers in systemic sclerosis. Int J Rheumatol 2011;2011:201787.
9. Yu EP, Ostor AJ, Hall FC. Successful treatment with bosentan for severe digital ischaemia in limited cutaneous systemic sclerosis. Ann Rheum Dis 2007;66:1122.
10. Nguyen VA, Eisendle K, Gruber I et al. Effect of the dual endothelin receptor antagonist bosentan on Raynaud's phenomenon secondary to systemic sclerosis: a double-blind prospective, radomized, placebocontrolled pilot study. Rheumatology 2010;49:583-7.